China PharmaHub Corp. Retains Stern IR for Investor Relations Services

BOSTON, Nov. 22, 2010 /PRNewswire-FirstCall/ -- China PharmaHub Corp. (OTC Bulletin Board: CPHB), a biopharmaceutical acquisition and development company, announced today that it has retained Stern Investor Relations, Inc. to develop and implement a comprehensive investor relations program for the Company. Stern IR specializes in working with entrepreneurial healthcare companies, including in the biotechnology sector.

The firm will provide strategic counsel and execution, will help communicate China PharmaHub's  vision to collaborate efforts to license, develop and commercialize products and technologies globally and within China and will support the Company's efforts to establish additional partnerships and relationships in the healthcare and financial communities.

"We are very pleased to be working with an experienced, well-respected firm like Stern IR, particularly at this pivotal period of growth for China PharmaHub, as we continue to develop our broad pipeline of development candidates in China and seek to establish new collaborations for medical development between China and other countries around the world, particularly in Europe and the United States," said Richard Lui, CEO of China PharmaHub.

About PharmaHub:

China PharmaHub Corp. is a development stage company engaged in the business of licensing, developing and commercializing innovative products for a wide variety of human diseases from biopharmaceutical companies based in the United States or China. PharmaHub brings a unique blend of relationships and resources to assist scientists and companies to develop, commercialize, market and sell pharmaceutical, biotechnology and related technologies, offer improved, cost-effective alternatives to current methods of treatment or enable the discovery, research and development of new medicines. PharmaHub's corporate headquarters are located in Los Angeles and Boston. For more information visit www.chnpharmahub.com.

About Stern Investor Relations

Stern Investor Relations, Inc. (Stern IR) is a leading investor relations firm providing a full range of consulting services to entrepreneurial companies in the biotechnology, healthcare and clean tech industries, focused on effectively managing communications with the investment community.  Committed to superior client service, Stern IR provides each client with senior level attention, strategic counsel and critical, disciplined tactical support. Since its inception in 1998, Stern IR has worked with more than 200 biotechnology, pharmaceutical and clean tech companies, including public, private, and pre-IPO companies in all stages of development. Stern IR is based in New York City. For more information, please visit www.sternir.com.

SOURCE China PharmaHub Corp.